CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens & Companies
Added: (Thu Mar 07 2019)
Pressbox (Press Release) -
Access full Research:
https://www.renub.com/car-t-cell-therapy-market-p.php
Get Free Customization in This Report
CAR T Cell therapy market is expected to grow with a CAGR of over 46 percent in the forecast period. Year 2017 has created new milestone for the oncology patients as FDA approved the first two CD19-targeted (Chimeric Antigen Receptor) CAR T cell therapies developed by Novartis and Gilead Sciences/Kite Pharma in the United States. These two approvals will certainly help to boost the global CAR T cell therapy market as more players are looking this big opportunities to enter the market place. At present over 200 CAR T clinical trials are running or completed across various parts of the world.
Rising number of adults and children developing cancer, increasing government initiatives for promoting research for cell therapy in cancer and rising number of clinical trials globally are some of the key drivers for the global CAR T Cell therapy market; however high cost of CAR T cell therapy treatment and regulatory challenges are key inhibitors for this market.
Request a free sample copy of the report: https://www.renub.com/contactus.php
Renub Research latest study report CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others) Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33,HER1, HER2, MESO, EGFRvII) Companies (Novartis,Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad) provides a detailed and comprehensive insight of the global CAR T cell therapy market.
This report studies the Global CAR T cell therapy market from 2 key view points by CAR T cell therapy market and CAR T cell therapy studies. Market segments are further studied by geographical regions and targeted antigens whereas CAR T cell therapy studies by targeted antigens globally and China specific. The report provides a complete analysis of the key Growth Drivers and Challenges, SWOT analysis, market, and their projections for the upcoming years (2028).
The report has been analyzed from 9 major viewpoints
1. Targeted Antigen - Global CAR T Cell Therapy Market
2. Regional CAR T Cell Therapy Market
3. Global CAR T Cell Therapy Clinical Trials/Study
4. China CAR T Cells Clinical Trials Details
5. CAR T Cell Therapy SWOT Analysis
6. The Regulation in CAR T Cell Therapy
7. Global - IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market
8. Growth Drivers and Challenges
9. Key CAR T companies Initiatives and Financial Insight
Targeted Antigens - Global CAR T Cell Therapy Market & Forecast
CD19
CD20
GD2
CD22
CD30
CD33
HER2
MESO
EGFRvII
Others
Regional CAR-T Cell Therapy Market & Forecast
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Global CAR T Cell Therapy Clinical Trials/Study
CD19
CD20
GD2
CD22
CD30
CD33
HER1
HER2
MESO
EGFRvII
China CAR T Cells Clinical Trials Details
By Cities CAR T Cells Clinical Trials
CD19 Directed CAR T Cells Clinical Trials
Non-CD19 Directed CAR T Cells Clinical Trials
Solid Tumors CAR T Cells Clinical Trials
The Regulation in CAR T Cell Therapy
United States
European Union
China
IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market
Venture Capital Investment
Initial Public Offerings
Strategic Partnerships/Deals
Key CAR T Technology Deals
Key Companies covered in this report are
Novartis
Gilead Sciences (Kite Pharma)
Celgene Corporation (Juno Therapeutics)
Celyad
Contact Us
Email: info@renub.com
Phone: +1-678-302-0700
Web: www.renub.com